| Revenue growth | 133% YoY consolidated growth in FY26. |
|---|---|
| Margins | Targeting 17% EBITDA margin for FY27. |
| Demand visibility | Strong; 50% revenue from long-term supply contracts. |
| Management confidence | High; projecting ₹750cr revenue for FY27. |
Growth
FY26 consolidated revenue rose 133% to ₹381cr; Standalone revenue grew 30% to ₹162cr with PAT up 64%.
Outlook
FY27 revenue guidance of ₹750cr with 17% EBITDA margin. Ongoing ₹440cr capex program for India and Australia.
Risks
H1 performance typically weaker (40% vs 60% in H2); reliance on CMOs until Australian facility commissioning.
Earnings Call filed with NSE, NSE: SAIPARENT. Summary written with AI assistance from the document.
Sai Parenterals Ltd: key numbers
- Share price
- ₹503.95
- Market cap
- ₹2,226 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 107.2×Sector 50.4×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 4.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Annual General Meeting
Sai Parenterals held its 25th Annual General Meeting on September 10, 2026. Shareholders approved financial statements, director appointments, and various company resolutions.
Sai Parenterals Earnings Call Transcript: Key Takeaways
Management is pivoting to acquisitions after regulatory shifts blocked organic expansion in Hyderabad. While revenue growth appears strong due to the Numed consolidation, margins were hurt by high logistics costs in Australia.
Sai Parenterals Investor Presentation: Key Takeaways
Sai Parenterals is transitioning from a domestic-focused player to an export-driven CDMO/branded generic platform through major acquisitions and capacity expansion. Q1 FY27 presentation focuses on IPO proceeds variation and global accreditation strategy.
Sai Parenterals Q1 FY27 Results: Net Profit ₹7.9 Cr, Up 464.3% YoY
Sai Parenterals Ltd reported revenue from operations of ₹178.7 Cr (+435.0% YoY) and net profit of ₹7.9 Cr (+464.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹7.9 Cr · +464.3% YoY
Sai Parenterals Earnings Call: Key Takeaways
Sai Parenterals reports Q4 FY26 consolidated revenue of ₹198cr and EBITDA of ₹29cr, following the Noumed acquisition. Standalone FY26 PAT grew 64% YoY.
Sai Parenterals Q3 FY26 Results: Net Loss of ₹6.7 Cr
Sai Parenterals Ltd reported revenue from operations of ₹96.2 Cr and a net loss of ₹6.7 Cr for Q3 FY26.
- Key figure
- Net loss ₹6.7 Cr